Tokyo-based Terumo Corp. has agreed to acquire Sequent Medical Inc. for $280 million and up to $100 million in commercial milestones, in a bid to get its hands on the CE-marked Web system for the treatment of cerebral aneurysms. Terumo plans to bring the system to the U.S. market following the completion of its ongoing pivotal trial for FDA approval.